Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Nasal Spray (WL1006) in Overweight or Obese Adults
NCT07465965Phase 1Recruiting
- Sponsor
- Shanghai World Leader Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Aug 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of semaglutide buccal patch (BUCCAL-PEP) in obesity (3 cohorts), sponsored by Shanghai World Leader Pharmaceutical. Primary endpoints: Maximum Plasma Concentration, Time to maximum concentration and 2 more. Started Mar 2026; status: recruiting.
02
Drugs
semaglutide buccal patch (BUCCAL-PEP)
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07465965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07465965.